Patient Name : Ms. BHAVYA THEJA Reg. No.

: PCL751471
Age and Sex : 28 Yrs / Female PCC Code : PCL-TS-622H
Referring Doctor : self Sample Drawn Date : 01-Jun-2025 08:15 AM
Referring Customer : SE1Q2R Registration Date : 01-Jun-2025 03:12 PM
Vial ID : Q0865597 Report Date : 01-Jun-2025 04:31 PM
Sample Type : WB-EDTA Report Status : Final Report
Client Address :

HEMATOLOGY
Test Name Obtained Value Units Bio. Ref. Intervals Method
(Age/Gender specific)

Complete Blood Count (CBC)

Haemoglobin 11.8 g/dL 11.5-15.5 Colorimetric
RBC Count 3.8 10^12/L 4.5-5.5 Electrical Impedance
Haematocrit (HCT) 33.1 % 40-50 Calculated
MCV 87.8 fl 83-101 RBC Histogram
MCH 31.2 pg 27-32 Calculated
MCHC 35.5 g/dL 31.5-34.5 Calculated
RDW-CV 17.9 % 11.6-14.0 RBC Histogram
Platelet Count 255 10^9/L 150-410 Electrical
Impedance/Microscopy
WBC count, Total 9.4 10^9/L 4.0-10.0 Impedance
Neutrophils 47.0 % 40-70 Microscopy
Neutrophil-Absolute Count 4.4 10^9/L 2.0-7.0 Calculated
Lymphocytes 47.0 % 20-40 Microscopy
Lymphocytes-Absolute Count 4.4 10^9/L 1.0-3.0 Calculated
Monocytes 4.0 % 2-10 Microscopy
Monocytes-Absolute Count 0.4 10^9/L 0.2-1.0 Calculated
Eosinophils 2.0 % 1-6 Microscopy
Eosinophils-Absolute Count 0.2 10^9/L 0.02-0.5 Calculated
Basophils 0.0 % 0-2 Microscopy
Basophils-Absolute Count 0.0 10^9/L 0.0-0.3 Calculated
Others 0.0 % 00 Microscopy
Remarks 0.00
Sample is Processed on Automated CBC Analyzer
Note: Haematocrit (HCT) is derived from calculated MCV based on RBC Histogram as per Manufacturer's Manual

Page 1 of 8
 Patient Name : Ms. BHAVYA THEJA Reg. No. : PCL751471
Age and Sex : 28 Yrs / Female PCC Code : PCL-TS-622H
Referring Doctor : self Sample Drawn Date : 01-Jun-2025 08:15 AM
Referring Customer : SE1Q2R Registration Date : 01-Jun-2025 03:12 PM
Vial ID : Q0865597, Q0865595, Q0865606 Report Date : 01-Jun-2025 06:49 PM
Sample Type : WB-EDTA , Serum, Plasma-Sodium Report Status : Final Report
Client Address :

CLINICAL BIOCHEMISTRY
Test Name Obtained Value Units Bio. Ref. Intervals Method
(Age/Gender specific)

*Glycosylated 5.00 % <5.7:Normal HPLC

Hemoglobin(GHb/HbA1c) 5.7-6.4:Prediabetic
6.5:Diabetic
*Glycosylated Hemoglobin 31.15 mmol/mol Calculated
*Mean Blood Glucose 96.80 mg/dL 90 - 120 : Excellent Control 121 - Calculated
150 : Good Control 151 - 180 :
Average Control 181 - 210 : Action
Suggested >211 :Panic Value
Comments:

HbA1c is an indicator of glycemic control. HbA1c represents average Glycemia over the past six to eight weeks. Glycation of Hemoglobin occurs over the entire 120 day life span of the Red Blood Cell, but within
this 120 days. Clinical studies suggest that a patient in stable control will have 50% of their HbA1c formed in the month before sampling, 25% in the month before that, and the remaining 25% in months two to
four.
Mean Plasma Glucose mg/dL = 28.7 x A1C - 46.7. Correlation between HbA1c and Mean Plasma Glucose (MPG) is not "perfect" but rather only this means that to predict or estimate average glucose from HbA1c
or vice-versa is not "perfect" but gives a good working ballpark estimate.
Afternoon and evening results correlate more closely to HbA1c than morning results, perhaps because morning fasting glucose levels vary much more than daytime Glucose levels, which are easier to predict
and control. As per IFCC recommendations 2007, HbA1c being reported as above maintaining traceability to both IFCC (mmol/mol) & NGSP (%) units.
Reference: ADA (American Diabetic Assosciation) Guidelines 2023.

*25 - Hydroxy Vitamin D- Serum 9.44 ng/mL Deficiency - < 20 CLIA

Insufficiency - 20 -30
Sufficiency - 30 - 100
Toxicity - >100
Comments:

25 OH Vitamin D is total of Vitamin D in Bone and mineral metabolism was recognized from its first identification as a factor that could cure rickets. However, Vitamin D is now recognized as a prohormone which
has multiple roles in maintaining optimal health.
Vitamin D toxicity is a recognized problem but a rare occurrence. Instead, a recent growing public health problem is Vitamin D insufficiency.

*Blood Urea Nitrogen (BUN) 7 mg/dL 6.0-20.0 Urease

Comments:
BUN is the end product of the protein metabolism. It is synthesized in the Liver from the Ammonia produced by the catabolism of Amino Acids.
It is transported by the Blood to the Kidneys from where it is excreted.
Increased levels are found in renal diseases, urinary obstructions, shock, congestive Heart failure and burns.
Decreased levels are found in Liver failure and pregnancy.

*Glucose-Blood-Fasting 89.0 mg/dL Normal < 100 GOD-POD

Pre-diabetic 100-125
Diabetic >= 126
Comments:

Glucose is the major carbohydrate present in blood. Its oxidation in the cells is the source of energy for the body. Increased levels of Glucose are found in Diabetes Mellitus, Hyperparathyroidism, Pancreatitis
and renal failure.
Decreased levels are found in Insulinoma, Hypothyroidism, Hypopituitarism and extensive Liver disease

Biological Reference Interval : Source: American Diabetic Association, Diabetes Care 2018:41 (Suppl.1) S13-S27

Page 2 of 8
 Patient Name : Ms. BHAVYA THEJA Reg. No. : PCL751471
Age and Sex : 28 Yrs / Female PCC Code : PCL-TS-622H
Referring Doctor : self Sample Drawn Date : 01-Jun-2025 08:15 AM
Referring Customer : SE1Q2R Registration Date : 01-Jun-2025 03:12 PM
Vial ID : Q0865597, Q0865595, Q0865606 Report Date : 01-Jun-2025 06:49 PM
Sample Type : WB-EDTA , Serum, Plasma-Sodium Report Status : Final Report
Client Address :

CLINICAL BIOCHEMISTRY
Test Name Obtained Value Units Bio. Ref. Intervals Method
(Age/Gender specific)

*Thyroid Stimulating Hormone 3.0097 µIU/mL 0.38-5.33 CMIA

(TSH)
Biological Reference Intervals : TSH(μlU/mL)
Pregnancy (As per American Thyroid Association)
1 Trimester 0.10-2.50
2 Trimester 0.2-3.00
3 Trimester 0.3-3.00
Interpretation:
Assay results should be interpreted in context to the clinical condition and associated results of other investigations.
Previous treatment with Corticosteroid therapy may result in lower TSH levels while Thyroid hormone levels are normal.
Results are invalidated if the client has undergone a radionuclide scan within 7-14 days before the test.
Abnormal Thyroid test findings often found in critically ill clients should be repeated after the critical nature of the condition is resolved.
The production, circulation, and disposal of Thyroid hormone are altered throughout the stages of pregnancy.

Albumin/Creatinine Ratio
Albumin Serum 3.84 g/dL 3.5-5.0 Bromocresol
green
Creatinine - Serum 0.73 mg/dL 0.6-1.2 Kinetic Alkaline
Picrate
Albumin/Creatinine Ratio 5.26 mg/g Refer to below table Calculated
Albuminuria Categories in CKD
Category ACR (mg/g) Terms
A1 <30 Normal to mildly increased
A2 30-300 Moderately increased*
A3 >300 Severely increased**
Abbreviations: ACR: Albumin-to-Creatinine Ratio; CKD: Chronic Kidney Disease.
*Relative to young adult level.
**Including Nephrotic Syndrome (Albumin excretion ACR >2220 mg/g)

Result rechecked and verified for abnormal cases.

*** End Of Report ***

Page 3 of 8
 Patient Name : Ms. BHAVYA THEJA Reg. No. : PCL751471
Age and Sex : 28 Yrs / Female PCC Code : PCL-TS-622H
Referring Doctor : self Sample Drawn Date : 01-Jun-2025 08:15 AM
Referring Customer : SE1Q2R Registration Date : 01-Jun-2025 03:12 PM
Vial ID : Q0865595 Report Date : 01-Jun-2025 05:19 PM
Sample Type : Serum Report Status : Final Report
Client Address :

CLINICAL BIOCHEMISTRY
Test Name Obtained Value Units Bio. Ref. Intervals Method
(Age/Gender specific)

Liver Function Test (LFT)

Bilirubin Total 0.49 mg/dL 0.1 - 1.2 Diazo Reaction
Bilirubin Direct 0.18 mg/dL 0 - 0.3 Diazo Reaction
Bilirubin Indirect 0.31 mg/dL 0.2 - 1.0 Calculated
Alkaline Phosphatase (ALP) 73.0 U/L 39-119 IFCC, Kinetic
Aspartate Aminotransferase (SGOT) 13.7 U/L < 45 IFCC, Kinetic
Alanine Transaminase (ALT/SGPT) 12.6 U/L < 45 IFCC, Kinetic
Gamma Glutamyl Transferase 10.6 U/L < 30 GLUPA-C
(GGT)
Protein Total 6.0 g/dL 6.0 -8.3 Biuret
Albumin 3.8 g/dL 3.2 - 5.0 BCG
Globulin 2.16 g/dl 2.5 - 3.8 Calculated
Albumin / Globulin Ratio 1.8 1.0 - 2.1 Calculated
*Liver function tests are blood tests used to help diagnose and monitor Liver disease or damage. Screen for Liver infections, such as Hepatitis, monitor possible side effects of medications.Measure the severity of a disease,
particularly scarring of the Liver (Cirrhosis)
*Alanine Transaminase (ALT)- an enzyme found in the Liver that helps your body metabolize protein. When the Liver is damaged, ALT is released into the bloodstream and levels increase.
*Aspartate Transaminase (AST)- an enzyme that helps metabolize Alanine, an amino acid. Like ALT, AST is normally present in blood at low levels. An increase in AST levels may indicate Liver damage or disease or Muscle
damage.
*Alkaline Phosphatase (ALP)- an enzyme in the Liver, bile ducts and bone. Higher-than-normal levels of ALP may indicate liver damage or disease, such as a blocked bile duct, or certain bone diseases.
*Albumin and Total Protein- Albumin is one of several proteins made in the Liver. Your body needs these proteins to fight infections and to perform other functions. Lower-than-normal levels of albumin and total protein might
indicate Liver damage or disease
*Bilirubin- a substance produced during the normal breakdown of red blood cells. Bilirubin passes through the liver and is excreted in stool. Elevated levels of bilirubin (jaundice) might indicate liver damage or disease or
certain types of anemia.
*Gamma-Glutamyltransferase (GGT)- GGT is an enzyme in the blood. Higher-than-normal levels may indicate liver or bile duct damage.

Result rechecked and verified for abnormal cases.

*** End Of Report ***

Page 4 of 8
 Patient Name : Ms. BHAVYA THEJA Reg. No. : PCL751471
Age and Sex : 28 Yrs / Female PCC Code : PCL-TS-622H
Referring Doctor : self Sample Drawn Date : 01-Jun-2025 08:15 AM
Referring Customer : SE1Q2R Registration Date : 01-Jun-2025 03:12 PM
Vial ID : Q0865595 Report Date : 01-Jun-2025 06:49 PM
Sample Type : Serum Report Status : Final Report
Client Address :

CLINICAL BIOCHEMISTRY
Test Name Obtained Value Units Bio. Ref. Intervals Method
(Age/Gender specific)

Lipid Profile
Cholesterol Total 171 mg/dL Adult: Desirable<200 mg/dL, Enzymatic
Borderline: 200 – 239 mg/dL,
High:>240 mg/dL
Cholesterol HDL 42.9 mg / dL 40 - 60 Direct
Homogenous
Cholesterol - LDL 117.78 mg/dL <100 Optimal Calculated
Cholesterol VLDL 10.32 mg/dL 7-40 Calculated
Non-HDL cholesterol 128.1 mg/dL Optimal < 130 Calculated
Triglycerides 51.6 mg/dL 35 - 170 GPO-POD
Cholesterol Total/Cholesterol HDL 4.0 0 - 4.0 Calculated
Ratio
Cholesterol LDL/Cholesterol HDL 2.7 0 - 3.5 Calculated
COMMENTS: Therapeutic target levels of lipids as per NCEP – ATP III recommendations:
Total Cholesterol (mg/dL) <200 - Desirable, 200-239 - Borderline High, >240 - High
HDL Cholesterol (mg/dL) <40 - Low, >60 - High
LDL Cholesterol (mg/dL) <100 Optimal, [Primary Target of Therapy], 100-129 - Near Optimal/Above Optimal,
130-159 - Borderline High, 160-189 - High, >190 Very High
Serum Triglycerides (mg/dL) <150 Normal, 150-199 Borderline High, 200-499 High, >500 Very High
NCEP recommends lowering of LDL Cholesterol as the primary therapeutic target with Lipid lowering agents, however, if Triglycerides remain >200 mg/dL after LDL goal is reached, set
secondary goal for non-HDL Cholesterol (total minus HDL) 30 mg/dL higher than LDL goal.
When Triglyceride level is > 400 mg/dL, Friedewald Equation is not applicable for calculation of LDL & VLDL. Hence the calculated values are not provided for such samples.
ATP III Guidelines:
Risk Category LDL Goal LDL Level at Which to LDL Level at Which to Consider Drug Therapy
Initiate Therapeutic
Lifestyle Changes (TLC)
CHD or CHD <100 mg/dL >100 mg/dL >130 mg/dL (100-129 mg/dL: drug optional)*
RiskEquivalents(10-year risk
>20%)
2+ Risk Factors <130 mg/dL >130 mg/dL 10-year risk 10-20%: >130 mg/dL 10-year risk <10%:>160mg/dL
(10-year risk <20%)
0-1 Risk Factor <160 mg/dL >160 mg/dL >190 mg/dL (160-189 mg/dL: LDL-lowering drug optional)

Page 5 of 8
 Patient Name : Ms. BHAVYA THEJA Reg. No. : PCL751471
Age and Sex : 28 Yrs / Female PCC Code : PCL-TS-622H
Referring Doctor : self Sample Drawn Date : 01-Jun-2025 08:15 AM
Referring Customer : SE1Q2R Registration Date : 01-Jun-2025 03:12 PM
Vial ID : Q0865595 Report Date : 01-Jun-2025 06:49 PM
Sample Type : Serum Report Status : Final Report
Client Address :

CLINICAL BIOCHEMISTRY
Test Name Obtained Value Units Bio. Ref. Intervals Method
(Age/Gender specific)

*Calcium 10.00 mg/dl 8.4-10.2 Arsenazo III

Complex
Interpretation:
Category Normal Ref. Range
Premature 6.2 mg/dL to 11.0 mg/dL
0 to 10 days 7.6 mg/dL to 10.4 mg/dL
10 days to 24 months 9.0 mg/dL to 11.0 mg/dL
Child 2 to 12 years 8.8 mg/dL to 10.8 mg/dL
Adult 8.4 mg/dL to 10.2 mg/dL
Male > 60 years 8.8 mg/dL to 10.0 mg/dL
Comments:
* Calcium in the body is found mainly in the bones (approximately 99%). In serum, Calcium exists in a free ionised form and in bound form (with Albumin). Hence, a
decrease in Albumin causes lower Calcium levels and vice-versa.
* Calcium levels in serum depend on the Parathyroid Hormone.
* Increased Calcium levels are found in Bone tumors, Hyperparathyroidism. decreased levels are found in Hypoparathyroidism, renal failure, Rickets.

*Vitamin - B12 87 pg/mL 120 - 914 CLIA

Comments:
Vitamin B12 is essential in DNA synthesis Hematopoiesis, and Central Nervous System integrity.
Its absorption depends on the presence of intrinsic factor (IF) and may be due to lack of IF secretion by gastric mucosa.
Vitamin B12 deficiency frequently causes Macrocytic Anemia, Glossitis, Pheripheral Neuropathy, Weakness, Hyperflexia, Ataxia, Loss of Proprioception, poor
coordination and effective behavioural changes. A significant increase in RBC MCV may be an important indicator of Vitamin B12 deficiency.

*Aspartate Aminotransferase 13.7 U/L < 45 IFCC, Kinetic

(SGOT)
*Alanine Transaminase 12.6 U/L < 45 IFCC, Kinetic
(ALT/SGPT)
*SGOT/SGPT Ratio 1 U/U >2.0 suggests alcoholic liver Calculated
disease.

Result rechecked and verified for abnormal cases.

*** End Of Report ***

Page 6 of 8
 Patient Name : Ms. BHAVYA THEJA Reg. No. : PCL751471
Age and Sex : 28 Yrs / Female PCC Code : PCL-TS-622H
Referring Doctor : self Sample Drawn Date : 01-Jun-2025 08:15 AM
Referring Customer : SE1Q2R Registration Date : 01-Jun-2025 03:12 PM
Vial ID : Q0865595 Report Date : 01-Jun-2025 06:38 PM
Sample Type : Serum Report Status : Final Report
Client Address :

CLINICAL BIOCHEMISTRY
Test Name Obtained Value Units Bio. Ref. Intervals Method
(Age/Gender specific)

Kidney Function Test (KFT) - III

Creatinine 0.73 mg/dL 0.6 - 1.2 Kinetic Alkaline
Picrate
Urea 15.0 mg/dL 13 - 45 Urease-GLDH
Uric Acid 3.8 mg/dL 3.6-7.2 Uricase
Urea / Creatinine Ratio 20.55 mg/mg Elevated ratio: >100:1 Calculated
Reduced ratio: <40:1

Page 7 of 8
 Patient Name : Ms. BHAVYA THEJA Reg. No. : PCL751471
Age and Sex : 28 Yrs / Female PCC Code : PCL-TS-622H
Referring Doctor : self Sample Drawn Date : 01-Jun-2025 08:15 AM
Referring Customer : SE1Q2R Registration Date : 01-Jun-2025 03:12 PM
Vial ID : Q0865622 Report Date : 01-Jun-2025 05:50 PM
Sample Type : Urine Report Status : Final Report
Client Address :

CLINICAL PATHOLOGY
Test Name Obtained Value Units Bio. Ref. Intervals Method
(Age/Gender specific)

Complete Urine Analysis (CUE)

PHYSICAL EXAMINATION
Colour Pale Yellow - Straw to light amber Visual
Examination
Appearence Clear - Clear Visual
Examination
CHEMICAL EXAMINATION
Glucose Negative Negative Glucose Oxidase
Protein Negative - Negative Protein-error-of-
indicator
Bilirubin (Bile) Negative - Negative Diazonium azo
Ketone Bodies Negative Negative Nitroprusside
Specific gravity 1.025 1.001 - 1.035 Hydrogenous
lonogen
Blood Negative Negative Peroxidase
Reaction (pH) 6.5 4.6 - 8.0 pH Indicator
Nitrites Negative Negative Diazonium
Leukocytes Negative Negative Pyrrole
MICROSCOPIC EXAMINATION
PUS(WBC) Cells 2-4 /hpf 00-05 Microscopy
Red Blood Cells Absent /hpf Absent Microscopy
U.Epithelial Cells 1-2 /hpf 00-05 Microscopy
Casts Absent /hpf Occasional Hyaline cast Microscopy
Crystals Absent /hpf Absent Microscopy
Others Absent /hpf Absent Microscopy

Correlate Clinically.
*** End Of Report ***

Page 8 of 8